Home › Research › Treatments
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F et al.. JAMA neurology, 2022-01-01
Topic: Amyloid, tau and blood-test diagnosis
Results Of 3285 included participants, the mean (SD) age was 70.4 (7.45) years; 1706 participants (52%) were female, 2661 (81%) had mild cognitive impairment due to Alzheimer disease, and 1777 (54%) used symptomatic medications for Alzheimer disease. Unless otherwise specified, all results represent analyses from the 10-mg/kg group.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., et al. (2022). Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA neurology. https://doi.org/10.1001/jamaneurol.2021.4161
Vancouver
Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA neurology. 2022. doi:10.1001/jamaneurol.2021.4161. PMID: 34807243.
BibTeX
@article{salloway2022-34807243,
author = {Salloway, S. and Chalkias, S. and Barkhof, F. and Burkett, P. and Barakos, J. and Purcell, D. and Suhy, J. and Forrestal, F. and others},
title = {{Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease}},
journal = {JAMA neurology},
year = {2022},
doi = {10.1001/jamaneurol.2021.4161},
pmid = {34807243},
url = {https://doi.org/10.1001/jamaneurol.2021.4161}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Of 3285 included participants, the mean (SD) age was 70.4 (7.45) years; 1706 participants (52%) were female, 2661 (81%) had mild cognitive impairment due to Alzheimer disease, and 1777 (54%) used symptomatic medications for Alzheimer disease.
- Unless otherwise specified, all results represent analyses from the 10-mg/kg group.
Why it matters
This report describes amyloid-related imaging abnormalities in two phase 3 studies of aducanumab in people with early Alzheimer disease. The provided text does not include information on whether aducanumab affected cognitive or functional outcomes.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants1,087
- Effect size41.3%; 1.4%; 35.2%
- Evidence strengthHigh
How this study scored 83/100
Published in a leading specialty journal, and it is a large phase 3 trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,087 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | 6 / 7 | Cited 608 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 101.3 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 6 / 6 | Cited 52.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 49 other studies in this library |
| Still being cited | 4 / 4 | Cited 366 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Karen Vossen Smirnakis: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34807243) |
| Free to read | 2 / 2 | Free to read |
| Total | 83 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2021.4161
- PubMed: 34807243
- Original source →
- Free full text: JAMA Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
49 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments
Also tagged “classification”
835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.